ClearPoint Neuro appoints renowned neurosurgeon Dr. Linda M. Liau to Board

ClearPoint Neuro, Inc.

Board expanded from 7 to 8 members; Dr. Liau appointed to newly created directorship effective Nov 2, 2021.
Dr. Liau is Professor and W. Eugene Stern Chair of Neurosurgery at UCLA, Co-Director of UCLA Brain Tumor Center.
She receives $40,000 annual retainer and initial equity grant valued at $120,000 vesting over one year.
Compensation includes annual equity grants of $120,000 on the day after each annual meeting.
No arrangements with any other person; no related-party transactions disclosed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Linda M. Liau

Director

CLPT · ClearPoint Neuro, Inc.

Effective: 2021-11-02
Filed: November 2, 2021, 7:59 PM ET

On November 2, 2021, the Board of Directors (the “ Board ”) of ClearPoint Neuro, Inc. (the “ Company ”) increased the size of the Board from seven to eight members, and, with the recommendation of the Corporate Governance and Nominating Committee of the Board, appointed Linda M. Liau, MD, PhD, MBA to fill the newly created directorship, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Linda M. Liau was appointed as Director at ClearPoint Neuro, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 2, 2021, the Board of Directors (the “ Board ”) of ClearPoint Neuro, Inc. (the “ Company ”) increased the size of the Board from seven to eight members, and, with the recommendation of the Corporate Governance and Nominating Committee of the Board, appointed Linda M. Liau, MD, PhD, MBA to fill the newly created directorship, effective immediately.

View on SEC.gov

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001171520-21-000432

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.